<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Dermatology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/dermatology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Vast majority of patients with thin melanomas alive at 20 years: study</title>
		<link>http://www.thedoctorschannel.com/view/vast-majority-of-patients-with-thin-melanomas-alive-at-20-years-study/</link>
		<pubDate>Fri, 16 Mar 2012 13:46:52 +0000</pubDate> 
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[acral lentiginous tumors]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[nodular tumors]]></category>
		<category><![CDATA[Queensland Cancer Registry]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=26851</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%, according to an analysis of data from the Queensland Cancer Registry. “We have confirmed that the outlook for patients with thin invasive melanomas is generally extremely positive, -]]></description>
		
			<media:content duration="1:25" medium="video">
		<media:title><![CDATA[Vast majority of patients with thin melanomas alive at 20 years: study]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%, according to an analysis of data from the Queensland Cancer Registry. “We have confirmed that the outlook for patients with thin invasive melanomas is generally extremely positive, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/vast-majority-of-patients-with-thin-melanomas-alive-at-20-years-study/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120316epid0041.jpg"/>
	<media:keywords><![CDATA[acral lentiginous tumors,melanoma,nodular tumors,Queensland Cancer Registry]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Diluted abobotulinum toxin A reduces wrinkles over larger area</title>
		<link>http://www.thedoctorschannel.com/view/diluted-abobotulinum-toxin-a-reduces-wrinkles-over-larger-area/</link>
		<pubDate>Fri, 20 Jan 2012 23:15:26 +0000</pubDate> 
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dysport]]></category>
		<category><![CDATA[Onabotulinum toxin]]></category>
		<category><![CDATA[wrinkles]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=23428</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A small study comparing two concentrations of abobotulinum toxin A (brand name, Dysport) in reducing forehead wrinkles indicates that greater dilution results in a larger surface area of effect. The finding suggests that diluting the product “may allow clinicians to achieve desired clinical outcomes while using modest doses of toxin,” -]]></description>
		
			<media:content duration="1:33" medium="video">
		<media:title><![CDATA[Diluted abobotulinum toxin A reduces wrinkles over larger area]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A small study comparing two concentrations of abobotulinum toxin A (brand name, Dysport) in reducing forehead wrinkles indicates that greater dilution results in a larger surface area of effect. The finding suggests that diluting the product “may allow clinicians to achieve desired clinical outcomes while using modest doses of toxin,” -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/diluted-abobotulinum-toxin-a-reduces-wrinkles-over-larger-area/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/01/Screen-shot-2012-01-20-at-6.14.17-PM.png"/>
	<media:keywords><![CDATA[Dysport,Onabotulinum toxin,wrinkles]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Combination therapy seems best for relief of psoriasis: report</title>
		<link>http://www.thedoctorschannel.com/view/combination-therapy-seems-best-for-relief-of-psoriasis-report/</link>
		<pubDate>Fri, 23 Dec 2011 18:50:05 +0000</pubDate> 
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[alfacept]]></category>
		<category><![CDATA[Corticosteroids]]></category>
		<category><![CDATA[etanercept]]></category>
		<category><![CDATA[psoralen]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[sirolimus]]></category>
		<category><![CDATA[tacrolimus]]></category>
		<category><![CDATA[UV-A]]></category>
		<category><![CDATA[UV-B]]></category>
		<category><![CDATA[Vitamin A]]></category>
		<category><![CDATA[Vitamin D]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22281</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – To combat psoriasis, a combination of topical therapies seems to work better than topical monotherapy, according to results of a systematic review and meta-analysis of published research. “It is important to consider combination treatment in the armamentarium of psoriasis therapy,” Dr. April W. Armstrong, director, Dermatology Clinical Research Unit, University -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Combination therapy seems best for relief of psoriasis: report]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – To combat psoriasis, a combination of topical therapies seems to work better than topical monotherapy, according to results of a systematic review and meta-analysis of published research. “It is important to consider combination treatment in the armamentarium of psoriasis therapy,” Dr. April W. Armstrong, director, Dermatology Clinical Research Unit, University -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/combination-therapy-seems-best-for-relief-of-psoriasis-report/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/Screen-shot-2011-12-27-at-2.02.56-PM.png"/>
	<media:keywords><![CDATA[alfacept,Corticosteroids,etanercept,psoralen,psoriasis,sirolimus,tacrolimus,UV-A,UV-B,Vitamin A,Vitamin D]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Check-ups may be safely reduced for early-stage melanoma patients</title>
		<link>http://www.thedoctorschannel.com/view/check-ups-may-be-safely-reduced-for-early-stage-melanoma-patients/</link>
		<pubDate>Sat, 12 Nov 2011 06:21:00 +0000</pubDate> 
				<category><![CDATA[Business of Medicine]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[check-ups]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>
		<category><![CDATA[melanoma]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/check-ups-may-be-safely-reduced-for-early-stage-melanoma-patients/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The number of monitoring visits for patients treated for localized primary melanoma can be reduced considerably, without having much effect on spotting any recurrent or new melanomas, according to an Australian study reported in the Journal of Clinical Oncology online November 7. “Current guidelines on the frequency of follow-up after -]]></description>
		
			<media:content duration="1:59" medium="video">
		<media:title><![CDATA[Check-ups may be safely reduced for early-stage melanoma patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The number of monitoring visits for patients treated for localized primary melanoma can be reduced considerably, without having much effect on spotting any recurrent or new melanomas, according to an Australian study reported in the Journal of Clinical Oncology online November 7. “Current guidelines on the frequency of follow-up after -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/check-ups-may-be-safely-reduced-for-early-stage-melanoma-patients/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4820.jpg"/>
	<media:keywords><![CDATA[check-ups,Journal of Clinical Oncology,melanoma]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Propranolol reduces size and redness of hemangiomas in infants and children</title>
		<link>http://www.thedoctorschannel.com/view/propranolol-reduces-size-and-redness-of-hemangiomas-in-infants-and-children/</link>
		<pubDate>Wed, 27 Jul 2011 19:46:00 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Neonatology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Otolaryngology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dr. Marcia Hogeling]]></category>
		<category><![CDATA[infantile hemangiomas]]></category>
		<category><![CDATA[infants]]></category>
		<category><![CDATA[pediatrics]]></category>
		<category><![CDATA[propranolol]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/propranolol-reduces-size-and-redness-of-hemangiomas-in-infants-and-children/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Oral propranolol given for 6 months stops the growth of infantile hemangiomas and decreases their volume and coloration, according to the results of a randomized trial reported in the August issue of Pediatrics. As the authors point out, propranolol has been shown to produce dramatic involution of infantile hemangiomas in -]]></description>
		
			<media:content duration="1:46" medium="video">
		<media:title><![CDATA[Propranolol reduces size and redness of hemangiomas in infants and children]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Oral propranolol given for 6 months stops the growth of infantile hemangiomas and decreases their volume and coloration, according to the results of a randomized trial reported in the August issue of Pediatrics. As the authors point out, propranolol has been shown to produce dramatic involution of infantile hemangiomas in -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/propranolol-reduces-size-and-redness-of-hemangiomas-in-infants-and-children/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4567.jpg"/>
	<media:keywords><![CDATA[Dr. Marcia Hogeling,infantile hemangiomas,infants,pediatrics,propranolol]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>DMARDs may decrease diabetes risk in RA and psoriasis</title>
		<link>http://www.thedoctorschannel.com/view/dmards-may-decrease-diabetes-risk-in-ra-and-psoriasis/</link>
		<pubDate>Fri, 24 Jun 2011 21:12:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[disease-modifying antirheumatic drugs]]></category>
		<category><![CDATA[DMARDs]]></category>
		<category><![CDATA[Dr. Daniel Solomon]]></category>
		<category><![CDATA[Journal of the American Medical Association]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<category><![CDATA[TNF]]></category>
		<category><![CDATA[tumor necrosis factor]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/dmards-may-decrease-diabetes-risk-in-ra-and-psoriasis/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Certain disease-modifying antirheumatic drugs (DMARDs) may lower the risk of diabetes in patients with rheumatoid arthritis (RA) or psoriasis, according to an observational study just published. Among nearly 14,000 patients with RA or psoriasis, researchers found that the use of a tumor necrosis factor (TNF) inhibitor or hydroxychloroquine was associated -]]></description>
		
			<media:content duration="1:48" medium="video">
		<media:title><![CDATA[DMARDs may decrease diabetes risk in RA and psoriasis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Certain disease-modifying antirheumatic drugs (DMARDs) may lower the risk of diabetes in patients with rheumatoid arthritis (RA) or psoriasis, according to an observational study just published. Among nearly 14,000 patients with RA or psoriasis, researchers found that the use of a tumor necrosis factor (TNF) inhibitor or hydroxychloroquine was associated -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/dmards-may-decrease-diabetes-risk-in-ra-and-psoriasis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4474.jpg"/>
	<media:keywords><![CDATA[diabetes,disease-modifying antirheumatic drugs,DMARDs,Dr. Daniel Solomon,Journal of the American Medical Association,psoriasis,RA,rheumatoid arthritis,TNF,tumor necrosis factor]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Psoriasis, obesity and high lipids tied in children</title>
		<link>http://www.thedoctorschannel.com/view/psoriasis-obesity-and-high-lipids-tied-in-children-2/</link>
		<pubDate>Tue, 24 May 2011 20:38:00 +0000</pubDate> 
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[Dr. Corinna Koebnick]]></category>
		<category><![CDATA[high lipids]]></category>
		<category><![CDATA[Journal of Pediatrics]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[psoriasis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/psoriasis-obesity-and-high-lipids-tied-in-children-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Overweight or obese children have a significantly higher prevalence of psoriasis and adolescents with psoriasis have elevated levels of blood lipids, researchers report in an April 29th on-line paper in The Journal of Pediatrics. Dr. Corinna Koebnick told Reuters Health by email that the findings not only suggest a link -]]></description>
		
			<media:content duration="1:12" medium="video">
		<media:title><![CDATA[Psoriasis, obesity and high lipids tied in children]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Overweight or obese children have a significantly higher prevalence of psoriasis and adolescents with psoriasis have elevated levels of blood lipids, researchers report in an April 29th on-line paper in The Journal of Pediatrics. Dr. Corinna Koebnick told Reuters Health by email that the findings not only suggest a link -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/psoriasis-obesity-and-high-lipids-tied-in-children-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4368.jpg"/>
	<media:keywords><![CDATA[children,Dr. Corinna Koebnick,high lipids,Journal of Pediatrics,obesity,psoriasis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Methotrexate and azathioprine both effective for severe eczema</title>
		<link>http://www.thedoctorschannel.com/view/methotrexate-and-azathioprine-both-effective-for-severe-eczema-2/</link>
		<pubDate>Mon, 02 May 2011 22:54:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[azathioprine]]></category>
		<category><![CDATA[cyclosporine]]></category>
		<category><![CDATA[Dr. Mandy Elvira Schram]]></category>
		<category><![CDATA[Journal of Allergy and Clinical Immunology]]></category>
		<category><![CDATA[methotrexate]]></category>
		<category><![CDATA[severe atopic dermatitis]]></category>
		<category><![CDATA[systemic corticosteroids]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/methotrexate-and-azathioprine-both-effective-for-severe-eczema-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Methotrexate and azathioprine are similarly effective as systemic treatments for severe atopic dermatitis in adults, according to the results of a head-to-head trial conducted in Europe. Cyclosporine and systemic corticosteroids are frequently used to treat severe eczema in adults, but both have drawbacks, the investigators point out in the Journal -]]></description>
		
			<media:content duration="1:52" medium="video">
		<media:title><![CDATA[Methotrexate and azathioprine both effective for severe eczema]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Methotrexate and azathioprine are similarly effective as systemic treatments for severe atopic dermatitis in adults, according to the results of a head-to-head trial conducted in Europe. Cyclosporine and systemic corticosteroids are frequently used to treat severe eczema in adults, but both have drawbacks, the investigators point out in the Journal -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/methotrexate-and-azathioprine-both-effective-for-severe-eczema-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4302.jpg"/>
	<media:keywords><![CDATA[azathioprine,cyclosporine,Dr. Mandy Elvira Schram,Journal of Allergy and Clinical Immunology,methotrexate,severe atopic dermatitis,systemic corticosteroids]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Azathioprine seen useful for some dermatologic conditions</title>
		<link>http://www.thedoctorschannel.com/view/azathioprine-seen-useful-for-some-dermatologic-conditions-2/</link>
		<pubDate>Thu, 14 Apr 2011 21:44:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Archives of Dermatology]]></category>
		<category><![CDATA[atopic dermatitis]]></category>
		<category><![CDATA[azathioprine]]></category>
		<category><![CDATA[Dr. Mandy E. Schram]]></category>
		<category><![CDATA[therapeutic]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/azathioprine-seen-useful-for-some-dermatologic-conditions-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Azathioprine has a moderate therapeutic effect in atopic dermatitis, and may also be useful for other dermatologic conditions, according to a report in the Archives of Dermatology for April. Dr. Mandy E. Schram, with the Academic Medical Center, University of Amsterdam, the Netherlands, and colleagues point out that azathioprine is -]]></description>
		
			<media:content duration="1:41" medium="video">
		<media:title><![CDATA[Azathioprine seen useful for some dermatologic conditions]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Azathioprine has a moderate therapeutic effect in atopic dermatitis, and may also be useful for other dermatologic conditions, according to a report in the Archives of Dermatology for April. Dr. Mandy E. Schram, with the Academic Medical Center, University of Amsterdam, the Netherlands, and colleagues point out that azathioprine is -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/azathioprine-seen-useful-for-some-dermatologic-conditions-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4257.jpg"/>
	<media:keywords><![CDATA[Archives of Dermatology,atopic dermatitis,azathioprine,Dr. Mandy E. Schram,therapeutic]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Actinic Keratosis in Patients with Solid Organ Transplants</title>
		<link>http://www.thedoctorschannel.com/view/actinic-keratosis-in-patients-with-solid-organ-transplants-2/</link>
		<pubDate>Thu, 31 Mar 2011 15:42:00 +0000</pubDate> 
				<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Actinic]]></category>
		<category><![CDATA[Goldenberg]]></category>
		<category><![CDATA[Keratoses]]></category>
		<category><![CDATA[Keratosis]]></category>
		<category><![CDATA[Mount Sinai]]></category>
		<category><![CDATA[pathology]]></category>
		<category><![CDATA[premalignant]]></category>
		<category><![CDATA[solid tumor]]></category>
		<category><![CDATA[squamous]]></category>
		<category><![CDATA[squamous cell]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/actinic-keratosis-in-patients-with-solid-organ-transplants-2/</guid>
		<description><![CDATA[Gary Goldenberg, MD, Assistant Professor of Dermatology and Pathology, and Medical Director of the Faculty Practice at the Mount Sinai School of Medicine, discusses the pathophysiology and approach to treatment for Actinic Keratosis in immunosuppressed patients. Related ReadingSwiss clinical practice guidelines for skin cancer in organ transplant recipients.Hofbauer GF, Anliker M, Arnold A, Binet I, -]]></description>
		
			<media:content duration="1:21" medium="video">
		<media:title><![CDATA[Actinic Keratosis in Patients with Solid Organ Transplants]]></media:title>
	<media:description><![CDATA[Gary Goldenberg, MD, Assistant Professor of Dermatology and Pathology, and Medical Director of the Faculty Practice at the Mount Sinai School of Medicine, discusses the pathophysiology and approach to treatment for Actinic Keratosis in immunosuppressed patients. Related ReadingSwiss clinical practice guidelines for skin cancer in organ transplant recipients.Hofbauer GF, Anliker M, Arnold A, Binet I, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/actinic-keratosis-in-patients-with-solid-organ-transplants-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4220.jpg"/>
	<media:keywords><![CDATA[Actinic,Dermatology,Goldenberg,Keratoses,Keratosis,Mount Sinai,pathology,premalignant,solid tumor,squamous,squamous cell]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
